The Week

IXJ.US rose 3.64% this week to $106.93, outperforming the S&P 500 by roughly 5.59 percentage points. The fund opened near $103.60 on Monday, dipped to $102.58 on Tuesday, then climbed through Thursday’s high of $107.995 before easing to $106.93 at Friday’s close, leaving a 5.23% weekly range.

Sector News

Healthcare names drew bids as investors rotated out of tech and into defensive, cash-flow-heavy sectors. J&J and UnitedHealth held post-earnings calls that highlighted resilient innovative medicine demand against softer MedTech trends, while AbbVie, Eli Lilly, and AstraZeneca reported clinical and regulatory progress. The broader market slipped on a stronger-than-expected inflation print, but healthcare held up, with major pharma stocks trading near record highs.

The Week Ahead

The immediate macro calendar is light on healthcare-specific items. US housing data on 19 October and 20 October, plus weekly EIA crude inventories on 21 October, will shape the broader risk tone and the pace of rotation between growth and defensive sectors. Watch whether the defensive bid in healthcare persists once the tech sell-off stabilises.

In Short

IXJ.US finished the week higher while the broader market fell, but the move came on uneven volume and a mid-range valuation of about 13.65x P/E. The latest session’s small-lot order flow was mixed. The key question for next week is whether healthcare’s defensive advantage holds against its own innovation pipeline headlines—or whether this was a short-term rotation spurt rather than a durable sector shift.

This article is generated by LongbridgeAI from market data, for information only and not investment advice.